-SEC Filing
SVB Leerink Maintains Outperform on AtriCure, Lowers Price Target to $75
SVB Leerink analyst Danielle Antalffy maintains AtriCure (NASDAQ:ATRC) with a Outperform and lowers the price target from $95 to $75.
Related Posts
Bruker Corp Preliminary Expectation For Revenue For Q4 2022 To Be Up Low Single Digits % YoY, A Result Of Organic Growth Of Mid-To-High Single Digits % YoY; Initial Guidance For 2023 For Organic Revenue Growth Up Mid-To-High Single Digit % YoY
On January 9, 2023 during its scheduled presentation at the 41st Annual J.P. Morgan Healthcare Conference, Bruker Corporation (the “Company”) stated that its current preliminary expectation for revenue for
ITeos Therapeutics Q3 EPS $1.86 Up From $(0.48) YoY
ITeos Therapeutics (NASDAQ:ITOS) reported quarterly earnings of $1.86 per share. This is a 487.5 percent increase over losses of $(0.48) per share from the same period last year.